·þÎñÈÈÏß
×ðÖØ¿Æѧ ¾´Î·ÖÆ¶È ×·ÇóЧÂÊ ¹Ø°®ÉúÃü
ѧÊõ¶¯Ì¬
GA»Æ½ð¼×¹¹½¨LOXO-292ÄÍÒ©Ë«Í»±ä¹¤³Ìϸ°ûÖêÖúÁ¦RETÒÖÖƼÁ¿ª·¢
Ðû²¼Ê±¼ä£º£º
2021-06-22
RET£¨Rearranged during transfection£©»ùÒòÓÚ1985ÄêÊ×´ÎÔÚÈËTÁÜ°ÍÁöϸ°ûÖз¢Ã÷£¬£¬£¬ÇÒ±»ÅжÏΪһ¸öÔ°©»ùÒò£¬£¬£¬RET»ùÒòλÓÚÈËÀà10ºÅ³£È¾É«Ì峤±Û£¨10q11.2£©£¬£¬£¬±àÂëÒ»ÖÖ±£´æÓÚϸ°ûĤÉϵÄÊÜÌåÀÒ°±Ëἤø£¨RTK£©[1]¡£¡£RETÂÑ°×ÔÚ³ÉÊìÀú³ÌÖУ¬£¬£¬ÂÑ°×Ç°Ìåͨ¹ý²î±ðµÄÑ¡ÔñÐÔ¼ôÇз½Ê½£¬£¬£¬Ö÷ÒªÐγÉÁ½ÖÖÂÑ°×ÑÇÐÍRET-9ºÍRET-51¡£¡£RET¼¤Ã¸±»Éñ¾½ºÖÊϸ°ûϵȪԴµÄÉñı»®ÑøÉú³¤Òò×ÓGDNF¼¤»î£¬£¬£¬GFNFÓëGFRα1Á¬ÏµÐγÉGDNF-GFRα1¸´ºÏÎ£¬£¬´Ë¸´ºÏÎïÔÙÓëRETÁ¬ÏµÐγÉÈý¸´ºÏÌ壬£¬£¬ÒýÆðRETµÄ¶þ¾Û»¯£¬£¬£¬²¢ÒýÆðÀÒ°±Ëá²Ð»ù×ÔÁ×Ëữ£¬£¬£¬´Ó¶ø¼¤»îÏÂÓÎÐźÅͨ·[2]£¬£¬£¬°üÀ¨RAS/MARK¡¢¡¢¡¢PI3K/AKT¡¢¡¢¡¢PLCγ/PKCµÈÐźÅͨ·£¬£¬£¬½ø¶øÒýÆðϸ°ûµÄÔöÖ³·Ö»¯¡¢¡¢¡¢Ç¨áã¡¢¡¢¡¢ÔÙÉúºÍÉú³¤µÈ[1]¡£¡£
ͼ1. a) RET¼¤Ã¸½á¹¹;b) RET¼¤Ã¸»î»¯»úÖƼ°ÐźÅͨ·¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[2])
RET»ùÒòÖ°©»úÖÆ£¬£¬£¬Ö÷ÒªÓлùÒòÈںϡ¢¡¢¡¢µãÍ»±ä¡¢¡¢¡¢»ùÒòÀ©ÔöºÍȾɫÌåÖØÅŵÈ[3]¡£¡£È¾É«ÌåµÄÖØ×é³£»áµ¼ÖÂRET»ùÒòÖÐÖÐÖ¹ÁѺóÓë²î±ðµÄÉÏÓλùÒò±¬·¢Èںϣ¬£¬£¬½ø¶øÐγÉÇý¶¯Ö×Áöϸ°ûÔöÖ³µÄÈںϻùÒò¡£¡£ÔÚ1990ÄêºÍ2012ÄêÏȺóÔÚ¼××´ÏÙÈéÍ·×´°©¡¢¡¢¡¢·ÎÏÙ°©ºÍÂýÐÔËèϵ°×Ѫ²¡Öз¢Ã÷ÕâÒ»±äÒì¡£¡£ÆäÖÐÈںϻùÒòÖ÷ÒªÓУº£ºKIF5B-RET£¨×î¶à£©£¬£¬£¬CCDC6-RETºÍNCOA4-RET£»RET»ùÒòÔÚNSCLC»¼ÕßÖ÷ÒªÒÔRET»ùÒòÈÚºÏÐÎʽ±¬·¢¸Ä±ä£¬£¬£¬Ñо¿ÏÔʾ·ÇСϸ°û·Î°©ÖÐKIF5B©\RETÈÚºÏÔ¼Õ¼ËùÓÐRETÈÚºÏµÄ 68.3 %£¬£¬£¬Æä´ÎΪCCDC6©\RET (16.8 %)¼°NCOA4©\RET (1.2 %)[4]¡£¡£ËäÈ»RET»ùÒòÔÚNSCLC»¼ÕßÖеķ¢²¡ÂʽöΪ1.4 %-2.5 %£¬£¬£¬¿ÉÊÇÎÒ¹úµÄ»¼Õß»ùÊýºÜÊǴ󣬣¬£¬Òò¶øЯ´øRET»ùÒòÈںϵÄNSCLC»¼Õß²¢²»ÉÙ¼û[5]¡£¡£µãÍ»±ä¶àλÓÚGate keeper²Ð»ù£¬£¬£¬Ö÷ÒªÊÇV804λµã£¨V804M£¬£¬£¬V804L£©£¬£¬£¬»¹°üÀ¨ÈܼÁÇ°ÑØÍ»±äG810λµã£¨G810R£¬£¬£¬G810S£¬£¬£¬G810C£¬£¬£¬G810A£¬£¬£¬G810V£©¡¢¡¢¡¢M918TºÍC634λµã£¨C634R£¬£¬£¬C634G£¬£¬£¬C634F£¬£¬£¬C634S£¬£¬£¬C634W£¬£¬£¬C634Y£¬£¬£¬C634K£©Í»±äµÈ[1]¡£¡£
ͼ2. ²î±ð°©Ö¢ÖÐRET»ùÒò¸Ä±äµÄ¸ÅÊö¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[3])
ͼ3. RET»ùÒòµÄÖ÷ÒªÈںϷ½Ê½ºÍµãÍ»±äλµã¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[1])
2011ÄêºÍ2013Ä꣬£¬£¬FDAºÍEMA»®·ÖÅú×¼VandetanibºÍCabozantinibÓÃÓÚÖÎÁÆÏ£ÍûµÄÍíÆÚµÄMTC»¼Õߣ¬£¬£¬²¢ÒÑÔÚRETÈÚºÏÑôÐÔNSCLC»¼ÕßÖÐÏÔʾ³ö»îÐÔ[1]¡£¡£µ«ÉÏÊöÒ©ÎïÕûÌå¹ØÓÚRET»ùÒòÈÚºÏÍ»±äµÄ°ÐÏòÌØÒìÐÔ²¢²»Ç¿£¬£¬£¬Æä²»µ«ÒÖÖÆRETÂÑ°×Ðźţ¬£¬£¬Í¬Ê±»áÒÖÖÆVEGFR¡¢¡¢¡¢EGFRµÈÆäËûÂÑ°×£¬£¬£¬ÓÐÓÃÐÔÏà¶Ô½Ï²î£¬£¬£¬ÇÒ¸±×÷ÓúͷǰÐÏò¶¾ÐÔÔöÌí¡£¡£2020Äê5ÔÂ9ÈÕ£¬£¬£¬FDA¼ÓËÙÅú×¼ÁËLoxo Oncology¹«Ë¾(ÀñÀ´ÆìÏÂ)selpercatinib(LOXO-292£¬£¬£¬Retevmo)ÉÏÊУ¬£¬£¬ÓÃÓÚÖÎÁƲ¿·ÖRETÈںϻùÒòµÄ·ÇСϸ°û·Î°©³ÉÈË»¼Õߣ¬£¬£¬ºÍÍíÆÚRETÍ»±äÑôÐÔ¼××´ÏÙËèÑù°©(MTC)»¼Õß¼°ÍíÆÚ»òתÒƵÄRETÈÚºÏÑôÐÔ¼××´ÏÙ°©»¼Õß¡£¡£ÕâÊÇFDAÅú×¼µÄÊ׿î¸ßÑ¡ÔñÐÔRET¼¤Ã¸ÒÖÖƼÁ¡£¡£Selpercatinib(LOXO-292)ÊÇ¿Ú·þÓÃÒ©µÄATP¾ºÕùÐÔС·Ö×ÓRET¼¤Ã¸ÒÖÖƼÁ£¬£¬£¬Ëü¾ßÓд©Í¸ÖÐÊàÉñ¾ÏµÍ³(CNS)µÄÄÜÁ¦£¬£¬£¬²¢ÇÒ¿ÉÒÔ°ÐÏò¼¤»îÐÔRETÈںϡ¢¡¢¡¢µãÍ»±äºÍijЩ»ñµÃÐÔÄÍÒ©Í»±ä(¶Ô°üÀ¨KIF5B-RETºÍCCDC6-RETÈÚºÏÀàÐÍ£¬£¬£¬ÒÔ¼°RET-V804L/MºÍM918TÄÍÒ©Í»±äÃô¸Ð)[1]¡£¡£2020Äê9ÔÂ5ÈÕ£¬£¬£¬FDAÅú×¼À¶Í¼¹«Ë¾(Blueprint Medicines Corporation)¿ª·¢µÄRETÒÖÖƼÁPralsetinib(BLU-667£¬£¬£¬Gavreto)ÉÏÊУ¬£¬£¬ÓÃÓÚÖÎÁÆRETÈÚºÏÑôÐÔתÒÆÐÔ·ÇСϸ°û·Î°©(NSCLC)³ÉÈË»¼Õß[1]¡£¡£2021Äê3ÔÂ24ÈÕ£¬£¬£¬BLU667(ÆÕÀÌæÄá, ÉÌÆ·Ãû£º£ºÆÕ¼ª»ª®)»ñµÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö(NMPA)Åú×¼£¬£¬£¬ÓÃÓÚ¼ÈÍù½ÓÊܹýº¬²¬»¯ÁƵÄRET»ùÒòÈÚºÏÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬£¬£¬³ÉΪº£ÄÚÊ׸öÒ²ÊÇÏÖÔÚΨһ»ñÅúµÄRETÒÖÖƼÁ[1]¡£¡£
²»¹ý£¬£¬£¬ÓÌÈçÆäËû°ÐÏòÒ©Ò»Ñù£¬£¬£¬ÄÍÒ©ÊDz»¿É×èÖ¹µÄ¡£¡£2020Äê1ÔÂ24ÈÕ£¬£¬£¬¡¶J Thorac Oncol¡·±¨µÀÁË2ÀýRETÈںϷÇСϸ°û·Î°©»¼ÕßÔÚʹÓÃLOXO-292ºó·ºÆðÈܼÁÇ°ÑØÍ»±ä(RET G810R/S/C)£¬£¬£¬½ø¶øµ¼ÖÂLOXO-292ÄÍÒ©¡£¡£½á¹¹Ä£×ÓÔ¤²â£¬£¬£¬RETÈܼÁÇ°ÑØÍ»±äG810R/S/C/VÍ»±äÔÚ¿Õ¼äÉÏ×è°ÁËSelpercatinibµÄÁ¬Ïµ£¬£¬£¬ÌåÍâÊÔÑé֤ʵ¿¹RET¶à¼¤Ã¸ÒÖÖƼÁMKIºÍÑ¡ÔñÐÔRET TKIs¾ùʧȥ»îÐÔ£¬£¬£¬Pralsetinib(BLU-667)¶ÔG810SÃô¸Ð[6]¡£¡£2021Äê4ÔÂ10ºÅ£¬£¬£¬Loxo Oncology¹«Ë¾±¨µÀ£¬£¬£¬ÔÚ»¼ÕßÖзºÆðRETÈܼÁÇ°ÑØÍ»±äG810λµãºÍÃÅ¿ØÍ»±äV804λµãµÄË«Í»±ä£¬£¬£¬¼°M918TλµãºÍÈܼÁÇ°ÑØÍ»±äG810λµãµÄË«Í»±ä¡£¡£ÌåÍâʵÑéЧ¹ûÏÔʾ£¬£¬£¬RET±¬·¢Ë«Í»±äºó£¬£¬£¬¶ÔSelpercatinib(LOXO-292)ºÍPralsetinib(BLU-667)ÒÖÖƼÁ²»Ãô¸Ð[7]¡£¡£
ͼ4. Ñ¡ÔñÐÔRETÒÖÖƼÁÄÍÒ©ÐÔµÄÄ£Äâ¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[6])
Õë¶ÔRET¼¤Ã¸ÒÖÖƼÁÒ©Î￪·¢ºÍÐèÇ󣬣¬£¬GA»Æ½ð¼×¹¹½¨Ò»ÏµÁÐBa/F3-RETË«Í»±äµÄ¹¤³Ìϸ°ûÖ꣬£¬£¬ÓÃÓÚÕë¶ÔRET°ÐµãµÄ»¯ºÏÎïɸÐò¼°¶¯ÎïҩЧÆÀ¼Û£¬£¬£¬½Ó´ý¿í´ó¿Í»§×ÉѯÏàÖú¡£¡£
ϸ°ûÖêÁбí
²¿·Öϸ°ûÖêÌåÍâÑéÖ¤Êý¾Ý
²¿·Öϸ°ûÖêÌåÄÚÄ£×ÓÑéÖ¤Êý¾Ý
BLU-667 in Ba/F3-KIF5B-RET Model
BLU-667¡¢¡¢¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804M Model
BLU-667¡¢¡¢¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804L Model
BLU-667¡¢¡¢¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810C Model
BLU-667¡¢¡¢¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810R Model
BLU-667¡¢¡¢¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810S Model
²¿·ÖCDXÄ£×ÓÑéÖ¤Êý¾Ý
LOXO-292 in LC-2/ad Model
LOXO-292 in TT Model
²Î¿¼ÎÄÏ×¼°Í¼Æ¬ÈªÔ´£º£º
1. The importance of the RET gene in thyroid cancer and therapeutic implications. Nature, 2021 May,17:296–306.
2. To Bud or not to Bud: The RET perspective in CAKUT. Pediatr Nephrol. 2014 Apr; 29(4): 597–608.
3. RET Aberrations in Diverse Cancers. Clin Cancer Res; 23(8) April 15, 2017,1988-1997.
4. Curigliano G, et al. 2021 ASCO, Poster 9089.
5.Öйú·ÇСϸ°û·Î°© RET »ùÒòÈÚºÏÁÙ´²¼ì²âר¼Ò¹²Ê¶. Öлª²¡ÀíѧÔÓÖ¾, 2021, 50(6): 583-591.
6. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Journal of Thoracic Oncology Vol. 2020.15 No. 4: 541-549.
7. Pre-clinical characterization of potent and selective next-generation RET inhibitors. Loxo Oncology at Lilly. Presented at: AACR Annual Meeting 2021.
GA»Æ½ð¼×¹«ÖÚºÅ
Á¢ÒìÒ©ÎïÆÀ¼Û
ÖпÆÒ½ÂöС³ÌÐò
µç»°£º£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©
0551—67129201£¨¹«Ë¾×ܲ¿£©
ÍøÖ·£º£ºwww.precedo.cn
µØµã£º£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¼Ò¿µ½¡´óÊý¾Ý¹¤ÒµÔ°A6¶°
Copyright © 2021 GA»Æ½ð¼× °æȨËùÓÐ | SEO±êÇ©
ÍøÕ¾½¨É裺£ºÖÐÆó¶¯Á¦ ºÏ·Ê